Chronic Kidney Disease (CKD) Drugs - Global Market Outlook (2017-2023)

Chronic Kidney Disease (CKD) Drugs - Global Market Outlook (2017-2023)

  • Published: July 2017
  • ID: SMRC16588

According to Stratistics MRC, the Global Chronic Kidney Disease (CKD) Drugs market is expected to grow from $12.87 billion in 2016 to reach $16.13 billion by 2023 with a CAGR of 3.2%. Drivers that are shaping the global market include, growing incidences of chronic kidney diseases, rise in aged population, rising incidence of diabetes and obesity related disorders, significant unmet requirements and beneficial reimbursement policies. On the other hand, factors such as intense competition from biosimilars and growing preferences of generic drugs are creating a negative impact on the market growth.

By end user, the hospital segment is anticipated to dominate the market globally. North America leads the global market with a largest market share driven by huge acceptance of advanced technological products.

Some of the key players profiled in this market include Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., AstraZeneca plc, Pfizer, Inc., Amgen Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., Keryx Biopharmaceuticals, Inc., Allergan plc., FibroGen Inc and Johnson & Johnson.

End Users Covered:
• Specialty Clinics
• Hospitals

Drug Classes Covered:
• Calcium channel blockers
• Antihypertensive
• Anemia Treatment Drugs
• Antihyperlipidemic
• Erythropoiesis-stimulating agents (ESAs)
• Swelling Treatment Drugs
• Beta blockers
• Diuretics
• Angiotensin-II receptor blockers
• ACE Inhibitors
• Other Drug Classes

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain     
o Rest of Europe 
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary      
        
2 Preface      
 
 2.1 Abstract      
 2.2 Stake Holders     
 2.3 Research Scope     
 2.4 Research Methodology    
  2.4.1 Data Mining    
  2.4.2 Data Analysis    
  2.4.3 Data Validation    
  2.4.4 Research Approach    
 2.5 Research Sources     
  2.5.1 Primary Research Sources   
  2.5.2 Secondary Research Sources   
  2.5.3 Assumptions    
        
3 Market Trend Analysis     
 3.1 Introduction     
 3.2 Drivers      
 3.3 Restraints     
 3.4 Opportunities     
 3.5 Threats      
 3.6 End User Analysis     
 3.7 Emerging Markets     
 3.8 Futuristic Market Scenario    
        
4 Porters Five Force Analysis     
 4.1 Bargaining power of suppliers    
 4.2 Bargaining power of buyers    
 4.3 Threat of substitutes    
 4.4 Threat of new entrants    
 4.5 Competitive rivalry     
        
5 Global Chronic Kidney Disease (CKD) Drugs Market, By End User 
 5.1 Introduction     
 5.2 Specialty Clinics      
 5.3 Hospitals      
        
6 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class 
 6.1 Introduction     
 6.2 Calcium channel blockers     
 6.3 Antihypertensive     
 6.4 Anemia Treatment Drugs    
 6.5 Antihyperlipidemic     
 6.6 Erythropoiesis-stimulating agents (ESAs)   
 6.7 Swelling Treatment Drugs    
 6.8 Beta blockers      
 6.9 Diuretics       
 6.10 Angiotensin-II receptor blockers    
 6.11 ACE Inhibitors      
 6.12 Other Drug Classes     
        
7 Global Chronic Kidney Disease (CKD) Drugs Market, By Geography 
 7.1 North America     
  7.1.1 US     
  7.1.2 Canada     
  7.1.3 Mexico     
 7.2 Europe      
  7.2.1 Germany     
  7.2.2 France     
  7.2.3 Italy     
  7.2.4 UK     
  7.2.5 Spain     
  7.2.6 Rest of Europe    
 7.3 Asia Pacific     
  7.3.1 Japan     
  7.3.2 China     
  7.3.3 India     
  7.3.4 Australia     
  7.3.5 New Zealand    
  7.3.6 Rest of Asia Pacific    
 7.4 Rest of the World     
  7.4.1 Middle East    
  7.4.2 Brazil     
  7.4.3 Argentina    
  7.4.4 South Africa    
  7.4.5 Egypt     
        
8 Key Developments      
 8.1 Agreements, Partnerships, Collaborations and Joint Ventures 
 8.2 Acquisitions & Mergers    
 8.3 New Product Launch    
 8.4 Expansions     
 8.5 Other Key Strategies    
        
9 Company Profiles      
 9.1 Hoffmann-La Roche Ltd.     
 9.2 GlaxoSmithKline plc.    
 9.3 Teva Pharmaceutical Industries Ltd.    
 9.4 Sanofi S.A.      
 9.5 AstraZeneca plc     
 9.6 Pfizer, Inc.      
 9.7 Amgen Inc.      
 9.8 Kissei Pharmaceutical Co., Ltd    
 9.9 AbbVie, Inc.     
 9.10 Keryx Biopharmaceuticals, Inc.   
 9.11 Allergan plc.     
 9.12 FibroGen Inc     
 9.13 Johnson & Johnson     


List of Tables       
1 Global Chronic Kidney Disease (CKD) Market Analysis, By Region (2015-2023) ($MN)
2 Global Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
3 Global Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics  (2015-2023) ($MN)
4 Global Chronic Kidney Disease (CKD) Market Analysis, By Hospitals  (2015-2023) ($MN)
5 Global Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
6 Global Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers  (2015-2023) ($MN)
7 Global Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
8 Global Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
9 Global Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
10 Global Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs)  (2015-2023) ($MN)
11 Global Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
12 Global Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers  (2015-2023) ($MN)
13 Global Chronic Kidney Disease (CKD) Market Analysis, By Diuretics  (2015-2023) ($MN)
14 Global Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers  (2015-2023) ($MN)
15 Global Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors  (2015-2023) ($MN)
16 Global Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
17 North America Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
18 North America Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
19 North America Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics  (2015-2023) ($MN)
20 North America Chronic Kidney Disease (CKD) Market Analysis, By Hospitals  (2015-2023) ($MN)
21 North America Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
22 North America Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers  (2015-2023) ($MN)
23 North America Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
24 North America Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
25 North America Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
26 North America Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs)  (2015-2023) ($MN)
27 North America Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
28 North America Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers  (2015-2023) ($MN)
29 North America Chronic Kidney Disease (CKD) Market Analysis, By Diuretics  (2015-2023) ($MN)
30 North America Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers  (2015-2023) ($MN)
31 North America Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors  (2015-2023) ($MN)
32 North America Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
33 Europe Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
34 Europe Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
35 Europe Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics  (2015-2023) ($MN)
36 Europe Chronic Kidney Disease (CKD) Market Analysis, By Hospitals  (2015-2023) ($MN)
37 Europe Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
38 Europe Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers  (2015-2023) ($MN)
39 Europe Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
40 Europe Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
41 Europe Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
42 Europe Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs)  (2015-2023) ($MN)
43 Europe Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
44 Europe Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers  (2015-2023) ($MN)
45 Europe Chronic Kidney Disease (CKD) Market Analysis, By Diuretics  (2015-2023) ($MN)
46 Europe Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers  (2015-2023) ($MN)
47 Europe Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors  (2015-2023) ($MN)
48 Europe Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
49 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
50 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
51 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics  (2015-2023) ($MN)
52 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Hospitals  (2015-2023) ($MN)
53 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
54 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers  (2015-2023) ($MN)
55 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
56 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
57 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
58 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs)  (2015-2023) ($MN)
59 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
60 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers  (2015-2023) ($MN)
61 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Diuretics  (2015-2023) ($MN)
62 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers  (2015-2023) ($MN)
63 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors  (2015-2023) ($MN)
64 Asia Pacific Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)
65 RoW Chronic Kidney Disease (CKD) Market Analysis, By Country (2015-2023) ($MN)
66 RoW Chronic Kidney Disease (CKD) Market Analysis, By End User (2015-2023) ($MN)
67 RoW Chronic Kidney Disease (CKD) Market Analysis, By Specialty Clinics  (2015-2023) ($MN)
68 RoW Chronic Kidney Disease (CKD) Market Analysis, By Hospitals  (2015-2023) ($MN)
69 RoW Chronic Kidney Disease (CKD) Market Analysis, By Drug Class (2015-2023) ($MN)
70 RoW Chronic Kidney Disease (CKD) Market Analysis, By Calcium channel blockers  (2015-2023) ($MN)
71 RoW Chronic Kidney Disease (CKD) Market Analysis, By Antihypertensive (2015-2023) ($MN)
72 RoW Chronic Kidney Disease (CKD) Market Analysis, By Anemia Treatment Drugs (2015-2023) ($MN)
73 RoW Chronic Kidney Disease (CKD) Market Analysis, By Antihyperlipidemic (2015-2023) ($MN)
74 RoW Chronic Kidney Disease (CKD) Market Analysis, By Erythropoiesis-stimulating agents (ESAs)  (2015-2023) ($MN)
75 RoW Chronic Kidney Disease (CKD) Market Analysis, By Swelling Treatment Drugs (2015-2023) ($MN)
76 RoW Chronic Kidney Disease (CKD) Market Analysis, By Beta blockers  (2015-2023) ($MN)
77 RoW Chronic Kidney Disease (CKD) Market Analysis, By Diuretics  (2015-2023) ($MN)
78 RoW Chronic Kidney Disease (CKD) Market Analysis, By Angiotensin-II receptor blockers  (2015-2023) ($MN)
79 RoW Chronic Kidney Disease (CKD) Market Analysis, By ACE Inhibitors  (2015-2023) ($MN)
80 RoW Chronic Kidney Disease (CKD) Market Analysis, By Other Drug Classes (2015-2023) ($MN)

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials